GG Parkiet – about the company’s financial results and plans for the coming months

A publication dedicated to the company’s financial results in the first half of 2017 and the company’s plans in terms of clinical development of drug candidates.
Maciej Wieczorek, PhD: Our generic drugs recorded similar sales rates to last year, which was in line with our expectations. Our financial result in the first half of the year was impacted by the lack of one-off (milestone) payments for the concluded agreements on the distribution of Salmex and discontinuation of manufacturing of Asaris for Polfarmex S.A. We have very ambitious plans for the development of our new drugs. Three of our innovative projects will begin clinical development this year. Over the next four years, at least 12 projects will reach the clinical development phase. We should receive the first results of the 2a phase which provides information on the efficacy and safety of drugs for 2-3 drugs in the first half of 2019. Then, in line with the previously provided information, we want to sign parenting agreements.
More information can be found at GG Parkiet (22.09.2017).